PriceTargets.com logo

Fresenius SE & Co. KGaA - FSNUY Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $39.34
  • Forecasted Upside: 448.71%
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$7.17 As of 01/26/2023 01:00 AM ET
▼ -0.2 (-2.71%)

This chart shows the closing price for FSNUY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Fresenius SE & Co. KGaA Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FSNUY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FSNUY

Analyst Price Target is $39.34
▲ +448.71% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Fresenius SE & Co. KGaA in the last 3 months. The average price target is $39.34, with a high forecast of $87.00 and a low forecast of $24.00. The average price target represents a 448.71% upside from the last price of $7.17.

This chart shows the closing price for FSNUY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 12 polled investment analysts is to buy stock in Fresenius SE & Co. KGaA. This rating has held steady since November 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
8/5/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
2/1/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
7/31/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
12/28/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2023

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/2/2023Jefferies Financial GroupUpgradeHold ➝ Buy
12/12/2022CitigroupInitiated CoverageBuy
11/28/2022UBS GroupUpgradeNeutral ➝ Buy
10/27/2022BarclaysLower TargetOverweight ➝ Overweight€35.00 ➝ €34.00
10/26/2022Credit Suisse GroupLower Target€30.00 ➝ €24.00
10/26/2022Deutsche Bank AktiengesellschaftLower Target€28.00 ➝ €25.00
10/26/2022Berenberg BankLower TargetBuy ➝ Buy€54.95 ➝ €46.10
10/18/2022Morgan StanleyInitiated CoverageEqual Weight
8/19/2022Berenberg BankLower Target€60.25 ➝ €54.95
8/12/2022HSBCUpgradeHold ➝ Buy
7/29/2022DZ BankDowngradeBuy ➝ Hold€26.00
5/31/2022BarclaysBoost TargetOverweight ➝ Overweight€50.50 ➝ €52.50
5/13/2022JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral€34.50 ➝ €33.30
5/10/2022HSBCDowngradeBuy ➝ Hold
5/6/2022Credit Suisse GroupBoost Target€35.00 ➝ €38.00
2/28/2022Credit Suisse GroupLower TargetNeutral ➝ Neutral€43.00 ➝ €35.00
2/25/2022Deutsche Bank AktiengesellschaftLower TargetHold ➝ Hold€38.00 ➝ €36.00
2/25/2022Societe GeneraleLower TargetBuy ➝ Buy€94.00 ➝ €87.00
2/24/2022JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral€42.30 ➝ €34.50
2/16/2022Berenberg BankBoost TargetBuy ➝ Buy€55.95 ➝ €60.25
12/1/2021Deutsche Bank AktiengesellschaftReiterated RatingHold
11/23/2021HSBCInitiated CoverageBuy
11/11/2021Jefferies Financial GroupUpgradeUnderperform ➝ Hold
11/9/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral
10/26/2021Deutsche Bank AktiengesellschaftReiterated RatingHold
9/10/2021BarclaysReiterated RatingOverweight
8/11/2021JPMorgan Chase & Co.Reiterated RatingOverweight
8/4/2021Societe GeneraleReiterated RatingBuy
8/2/2021Credit Suisse GroupReiterated RatingNeutral
7/23/2021BarclaysSet TargetOverweight$13.36
7/22/2021JPMorgan Chase & Co.Reiterated RatingOverweight
7/21/2021Morgan StanleyReiterated RatingOverweight
7/21/2021Deutsche Bank AktiengesellschaftReiterated RatingHold
7/21/2021UBS GroupUpgradeNeutral
5/12/2021DZ BankReiterated RatingBuy
4/28/2021BarclaysReiterated RatingOverweight
2/19/2021Berenberg BankReiterated RatingBuy
2/10/2021JPMorgan Chase & Co.Reiterated RatingOverweight
2/4/2021Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold
2/3/2021DZ BankReiterated RatingBuy
2/2/2021BarclaysReiterated RatingOverweight
1/6/2021Nord/LBReiterated RatingBuy
12/3/2020Bank of AmericaDowngradeBuy ➝ Neutral
11/26/2020DZ BankReiterated RatingBuy
11/10/2020Deutsche Bank AktiengesellschaftReiterated RatingBuy
11/2/2020Morgan StanleyReiterated RatingOverweight
9/23/2020BarclaysUpgradeEqual Weight ➝ Overweight
8/14/2020JPMorgan Chase & Co.Reiterated RatingOverweight
8/5/2020Jefferies Financial GroupDowngradeHold ➝ Underperform
6/1/2020BarclaysReiterated RatingEqual Weight
5/20/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight
5/19/2020JPMorgan Chase & Co.Reiterated RatingOverweight
4/27/2020BarclaysReiterated RatingEqual Weight
4/23/2020JPMorgan Chase & Co.Reiterated RatingOverweight
3/24/2020Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform
11/12/2019Sanford C. BernsteinInitiated CoverageOutperform ➝ Market Perform
3/22/2019The Goldman Sachs GroupReiterated RatingBuy
3/7/2019Jefferies Financial GroupReiterated RatingHold
1/15/2019BarclaysDowngradeOverweight ➝ Equal Weight
1/9/2019UBS GroupUpgradeSell ➝ Neutral
12/18/2018The Goldman Sachs GroupUpgradeNeutral ➝ Buy
(Data available from 1/27/2018 forward)

News Sentiment Rating

0.41 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/1/2022
  • 3 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
7/31/2022
  • 1 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/30/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2022
  • 3 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2022
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
11/28/2022
  • 3 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
12/28/2022
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/27/2023

Current Sentiment

  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Fresenius SE & Co. KGaA logo
Fresenius SE & Co. KGaA is a healthcare group, which engages in the provision of products and services for dialysis, hospitals, and outpatient medical care. It operates through the following segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed. The Fresenius Medical Care segment caters to individuals with renal diseases. The Fresenius Kabi segment specializes in lifesaving medicines and technologies. The Fresenius Helios offers expertise in inpatient and outpatient care as well as in telemedicine. The Fresenius Vamed segment manages projects and services for hospitals and other healthcare facilities. The company was founded by Eduard Fresenius on October 1, 1912 and is headquartered in Bad Homburg, Germany.
Read More

Today's Range

Now: $7.17
Low: $7.13
High: $7.28

50 Day Range

MA: $7.06
Low: $6.21
High: $7.75

52 Week Range

Now: $7.17
Low: $4.79
High: $10.99

Volume

18,098 shs

Average Volume

28,219 shs

Market Capitalization

$16.15 billion

P/E Ratio

8.74

Dividend Yield

2.20%

Beta

1.13

Frequently Asked Questions

What sell-side analysts currently cover shares of Fresenius SE & Co. KGaA?

The following Wall Street research analysts have issued reports on Fresenius SE & Co. KGaA in the last year: Barclays PLC, Berenberg Bank, Citigroup Inc., Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, DZ Bank AG, HSBC Holdings plc, Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, Societe Generale, and UBS Group AG.
View the latest analyst ratings for FSNUY.

What is the current price target for Fresenius SE & Co. KGaA?

7 Wall Street analysts have set twelve-month price targets for Fresenius SE & Co. KGaA in the last year. Their average twelve-month price target is $39.34, suggesting a possible upside of 448.7%. Societe Generale has the highest price target set, predicting FSNUY will reach $87.00 in the next twelve months. Credit Suisse Group AG has the lowest price target set, forecasting a price of $24.00 for Fresenius SE & Co. KGaA in the next year.
View the latest price targets for FSNUY.

What is the current consensus analyst rating for Fresenius SE & Co. KGaA?

Fresenius SE & Co. KGaA currently has 5 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe FSNUY will outperform the market and that investors should add to their positions of Fresenius SE & Co. KGaA.
View the latest ratings for FSNUY.

What other companies compete with Fresenius SE & Co. KGaA?

Other companies that are similar to Fresenius SE & Co. KGaA include Abiomed, Insulet, Teleflex, Baxter International and NovoCure. Learn More about companies similar to Fresenius SE & Co. KGaA.

How do I contact Fresenius SE & Co. KGaA's investor relations team?

Fresenius SE & Co. KGaA's physical mailing address is Else-Kroner-Strasse 1, Bad Homburg 2M, 61352. The company's listed phone number is (496) 172-6080 and its investor relations email address is [email protected] The official website for Fresenius SE & Co. KGaA is www.fresenius.com. Learn More about contacing Fresenius SE & Co. KGaA investor relations.